Begin main content

Call for Feedback: Rituximab to Treat Primary Membranous Nephropathy

February 13, 2020
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders. Rituximab to Treat Primary Membranous Nephropathy Call for Feedback: 2020-02-13 Feedback Due By: 2020-02-28 Consultation Document: Proposed Project Scope Product Type: Health Technology Assessment Submit Feedback

New at CADTH — February 2020

February 10, 2020
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

CADTH Pharmaceutical Reviews Update — Issue 13

February 6, 2020
See Pharmaceutical Reviews Update – Issue 13 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: New consolidated document for pCODR procedures and guidelines Clarifications regarding economic submission requirements Update for patients and communities For More Information

Drug Reimbursement Recommendation - Lorlatinib (Lorbrena) and Atezolizumab (Tecentriq)

January 30, 2020
Today, CADTH has issued final recommendations for: Lorlatinib (Lorbrena) NSCLC Funding Request: For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or...